Topic
13 stories from Planck Standard. Latest: July 15, 2026.
Phase 3 results showed young children with sickle cell disease or beta thalassemia became free of pain crises or transfusions after a single treatment that rewrites their own blood cells.
Life Biosciences began the first human trial of partial epigenetic reprogramming — a gene therapy built on David Sinclair's research that aims to make aging eye cells young again.
The Seattle research powerhouse is launching a Brain Health Accelerator aimed at gene therapies for Alzheimer's, Parkinson's, Huntington's and ALS that target diseased cells, not just proteins.
Researchers identified specific amygdala neurons whose imbalanced activity alone can trigger pathological behaviors, then successfully restored normal function.
Scientists behind Casgevy — the world's first CRISPR-based medicine — and Luxturna, the first gene replacement therapy to restore sight in children, were honored at the April 18 ceremony.
Jean Bennett, Albert Maguire, and Katherine High accepted the million prize for work that restored sight to patients with RPE65 mutations and opened the modern era of genetic medicine.
Stuart Orkin and Swee Lay Thein shared the $3 million prize for identifying the fetal hemoglobin switch that made the CRISPR therapy Casgevy possible — the first gene-editing treatment ever approved by the FDA.
The infant who received a custom-designed gene therapy built specifically for his unique genetic mutation marks his one-year anniversary walking, talking, and helping usher in a new FDA framework for individualized medicine.
A landmark trial published in Nature Medicine reports that one injection of a corrective gene into the inner ear transformed profound deafness into functional hearing in every participant — including a seven-year-old girl now having everyday conversations.
Single injection delivers working hearing gene to inner ear, with all ten patients showing improvement and some experiencing rapid gains in just one month.
Groundbreaking study shows all ten patients, from toddlers to young adults, experienced improved hearing after receiving working copy of OTOF gene.
Scientists develop targeted brain treatment that mimics morphine's benefits while avoiding addiction risks, using AI to map precise pain circuits.
Scientists at UNSW and St. Jude Children's Research Hospital demonstrated that removing methyl groups from silenced DNA can reactivate genes — potentially transforming treatment of sickle cell and other diseases.